Amneal Pharmaceuticals (NASDAQ:AMRX) Announces Earnings Results

by · The Cerbat Gem

Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) released its quarterly earnings results on Thursday. The company reported $0.27 earnings per share for the quarter, FiscalAI reports. The company had revenue of $722.52 million during the quarter. Amneal Pharmaceuticals had a negative return on equity of 272.31% and a net margin of 4.01%.

Amneal Pharmaceuticals Stock Performance

Shares of AMRX stock traded down $0.52 during trading hours on Friday, reaching $13.20. The company had a trading volume of 1,519,802 shares, compared to its average volume of 1,614,524. The stock has a fifty day moving average of $12.82 and a 200-day moving average of $12.73. The company has a market capitalization of $4.15 billion, a price-to-earnings ratio of 34.74 and a beta of 1.32. Amneal Pharmaceuticals has a 12-month low of $7.02 and a 12-month high of $15.42.

Wall Street Analyst Weigh In

AMRX has been the subject of a number of analyst reports. Truist Financial upped their price target on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Weiss Ratings reissued a “hold (c)” rating on shares of Amneal Pharmaceuticals in a report on Wednesday, January 21st. UBS Group assumed coverage on Amneal Pharmaceuticals in a report on Friday, April 17th. They set a “buy” rating and a $19.00 target price for the company. Finally, Zacks Research cut Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $15.00.

View Our Latest Analysis on AMRX

Institutional Investors Weigh In On Amneal Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. Convergence Investment Partners LLC grew its position in shares of Amneal Pharmaceuticals by 12.2% in the first quarter. Convergence Investment Partners LLC now owns 164,314 shares of the company’s stock valued at $2,042,000 after purchasing an additional 17,884 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Amneal Pharmaceuticals by 1.5% in the first quarter. Dimensional Fund Advisors LP now owns 5,690,586 shares of the company’s stock valued at $70,723,000 after purchasing an additional 81,546 shares in the last quarter. KBC Group NV purchased a new stake in shares of Amneal Pharmaceuticals in the first quarter valued at approximately $80,000. Freemont Management S.A. purchased a new stake in shares of Amneal Pharmaceuticals in the first quarter valued at approximately $3,978,000. Finally, Jennison Associates LLC grew its position in shares of Amneal Pharmaceuticals by 61.4% in the first quarter. Jennison Associates LLC now owns 124,898 shares of the company’s stock valued at $1,552,000 after purchasing an additional 47,497 shares in the last quarter. 31.82% of the stock is currently owned by hedge funds and other institutional investors.

About Amneal Pharmaceuticals

(Get Free Report)

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.

Featured Articles